UK rejects Roche’s Avastin in advanced breast cancer

LONDON, July 6 (Reuters) - Roche Holding AG's cancer drug Avastin has been rejected by Britain's healthcare cost agency as a first-line treatment for advanced breast cancer, the latest in a series of…
Read the full story: Reuters: Healthcare